Hologic stock (US4364401012): Analyst hold consensus with limited upside

Hologic maintains a hold rating from analysts with 2 buys and 13 holds, price target near current levels around $79. Shares traded at $76.07 recently amid diagnostics sector focus.

Hologic stock has garnered a consensus hold rating from Wall Street analysts, with an average score of 2.13 based on 2 buy ratings and 13 holds as of recent coverage tracked by MarketBeat. No strong buy or sell ratings were noted. The consensus price target stands at $79.09, suggesting limited near-term upside from recent levels around $76, according to MarketBeat as of May 2026. The company last reported quarterly earnings on January 29, 2026, providing context for ongoing investor interest.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Hologic, Inc.
• Sector/industry: Healthcare / Diagnostics & Medical Devices
• Headquarters/country: United States
• Core markets: North America, Europe
• Key revenue drivers: Women's health diagnostics, imaging systems
• Home exchange/listing venue: Nasdaq (HOLX)
• Trading currency: USD

Hologic: core business model

Hologic focuses on women's health, offering diagnostics, imaging, and surgical solutions. The company develops products for breast cancer screening, cervical cancer detection, and reproductive health. Its core technologies include digital mammography systems and molecular diagnostics platforms used in hospitals and clinics worldwide. Hologic's business model emphasizes innovation in precision medicine tailored to female health needs, serving as a key player for US healthcare providers. This positioning provides exposure to the growing demand for early detection technologies in the US market.

Main revenue and product drivers for Hologic

Diagnostics represent a primary revenue driver, with products like the Aptima assay for HPV testing and genital health. Imaging systems, including the Genius 3D Mammography, contribute significantly, capturing a substantial share of US breast screening procedures. Surgical products for hysteroscopy and endometrial ablation add diversity. In its Q1 fiscal 2026 earnings reported January 29, 2026, Hologic highlighted sustained demand in these areas amid post-pandemic recovery, according to company filings accessible via investor relations as of January 2026. These segments underscore Hologic's relevance to US investors tracking medtech growth.

Industry trends and competitive position

The diagnostics sector benefits from rising screening rates and AI integration in imaging. Hologic competes with GE Healthcare and Siemens Healthineers but holds a strong foothold in women's health niches. Recent industry data from IQVIA notes increased US adoption of 3D mammography, aligning with Hologic's portfolio strengths as of 2025 reports. The company's focus on molecular diagnostics positions it well against biotech peers amid personalized medicine trends.

Why Hologic matters for US investors

Hologic's Nasdaq listing and dominant US market share in mammography make it a direct play on American healthcare spending. With Medicare reimbursements supporting screening programs, the stock offers exposure to defensive medtech amid economic cycles. Its products are integral to US hospitals, providing stability for retail portfolios seeking healthcare allocation.

Conclusion

Hologic continues to execute in women's health diagnostics and imaging, supported by a hold consensus from analysts and recent earnings visibility. The stock's position near price targets reflects balanced views on growth prospects. Investors monitor upcoming quarters for sustained demand in core segments amid sector tailwinds.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.